AnaptysBio Ebit vs Gross Profit Analysis
ANAB Stock | USD 26.58 0.24 0.91% |
AnaptysBio financial indicator trend analysis is way more than just evaluating AnaptysBio prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AnaptysBio is a good investment. Please check the relationship between AnaptysBio Ebit and its Gross Profit accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.
Ebit vs Gross Profit
Ebit vs Gross Profit Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AnaptysBio Ebit account and Gross Profit. At this time, the significance of the direction appears to have very week relationship.
The correlation between AnaptysBio's Ebit and Gross Profit is 0.29. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Gross Profit in the same time period over historical financial statements of AnaptysBio, assuming nothing else is changed. The correlation between historical values of AnaptysBio's Ebit and Gross Profit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of AnaptysBio are associated (or correlated) with its Gross Profit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Gross Profit has no effect on the direction of Ebit i.e., AnaptysBio's Ebit and Gross Profit go up and down completely randomly.
Correlation Coefficient | 0.29 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Ebit
Gross Profit
Gross profit is a required income statement account that reflects total revenue of AnaptysBio minus its cost of goods sold. It is profit before AnaptysBio operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Most indicators from AnaptysBio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AnaptysBio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.At present, AnaptysBio's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 2.57, whereas Tax Provision is forecasted to decline to (4.2 K).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.5M | 21.1M | 18.1M | 19.0M | Depreciation And Amortization | 468K | 7.6M | 2.4M | 2.8M |
AnaptysBio fundamental ratios Correlations
Click cells to compare fundamentals
AnaptysBio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AnaptysBio fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 435.2M | 416.6M | 643.1M | 610.4M | 452.4M | 354.3M | |
Short Long Term Debt Total | 2.2M | 342K | 21.0M | 19.5M | 17.8M | 10.8M | |
Other Current Liab | 871K | 15.3M | 12.9M | 21.6M | 31.0M | 32.5M | |
Total Current Liabilities | 29.5M | 19.8M | 16.1M | 26.1M | 37.4M | 19.3M | |
Total Stockholder Equity | 405.0M | 396.7M | 356.4M | 262.1M | 88.1M | 83.7M | |
Property Plant And Equipment Net | 1.6M | 1.8M | 21.8M | 20.0M | 18.3M | 19.2M | |
Net Debt | (168.8M) | (250.1M) | (474.8M) | (51.9M) | (18.2M) | (19.1M) | |
Retained Earnings | (244.0M) | (264.0M) | (321.8M) | (450.5M) | (614.1M) | (583.4M) | |
Accounts Payable | 16.2M | 4.2M | 1.7M | 2.8M | 4.7M | 4.2M | |
Cash | 171.0M | 250.5M | 495.7M | 71.3M | 36.0M | 34.2M | |
Non Current Assets Total | 57.5M | 20.0M | 89.2M | 163.2M | 45.6M | 53.5M | |
Non Currrent Assets Other | 208K | 1.5M | 662K | 256K | 230.4K | 218.9K | |
Cash And Short Term Investments | 374.2M | 393.7M | 548.1M | 441.2M | 390.9M | 295.2M | |
Common Stock Shares Outstanding | 27.1M | 27.3M | 27.4M | 28.2M | 26.9M | 21.0M | |
Liabilities And Stockholders Equity | 435.2M | 416.6M | 643.1M | 610.4M | 452.4M | 354.3M | |
Non Current Liabilities Total | 654K | 4.6M | 270.5M | 322.2M | 326.8M | 343.2M | |
Other Current Assets | 3.5M | 2.9M | 4.9M | 4.5M | 9.1M | 9.5M | |
Other Stockholder Equity | 213.5M | 660.7M | 678.6M | 717.8M | 703.0M | 738.1M | |
Total Liab | 30.2M | 19.8M | 286.6M | 348.3M | 364.3M | 382.5M | |
Property Plant And Equipment Gross | 1.6M | 1.8M | 21.8M | 20.0M | 24.5M | 25.7M | |
Total Current Assets | 377.7M | 396.6M | 553.9M | 447.2M | 406.8M | 300.8M | |
Accumulated Other Comprehensive Income | 338K | (4K) | (422K) | (5.2M) | (797K) | (836.9K) | |
Short Term Debt | 2.2M | 342K | 1.5M | 1.6M | 1.8M | 2.3M | |
Other Liab | 796K | 654K | 251.1M | 304.4M | 350.1M | 367.6M | |
Net Tangible Assets | 405.0M | 396.7M | 627.0M | 584.3M | 672.0M | 705.6M | |
Other Assets | 208K | 139K | 18.2M | 256K | 294.4K | 279.7K | |
Property Plant Equipment | 3.0M | 1.8M | 2.3M | 2.1M | 2.4M | 1.6M | |
Capital Surpluse | 648.7M | 660.7M | 678.6M | 717.8M | 825.5M | 517.6M | |
Retained Earnings Total Equity | (244.0M) | (264.0M) | (321.8M) | (450.5M) | (405.4M) | (385.2M) | |
Short Term Investments | 203.2M | 143.2M | 52.4M | 369.9M | 354.9M | 252.1M | |
Capital Lease Obligations | 871K | 342K | 21.0M | 19.5M | 17.8M | 9.4M | |
Net Invested Capital | 406.4M | 396.7M | 356.4M | 262.1M | 88.1M | 83.7M | |
Long Term Investments | 54.3M | 17.5M | 67.1M | 142.9M | 27.0M | 25.7M |
Pair Trading with AnaptysBio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AnaptysBio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AnaptysBio will appreciate offsetting losses from the drop in the long position's value.Moving together with AnaptysBio Stock
0.61 | EGRX | Eagle Pharmaceuticals Earnings Call This Week | PairCorr |
Moving against AnaptysBio Stock
0.64 | QLI | Qilian International | PairCorr |
0.49 | SNDL | SNDL Inc Earnings Call This Week | PairCorr |
0.48 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
The ability to find closely correlated positions to AnaptysBio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AnaptysBio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AnaptysBio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AnaptysBio to buy it.
The correlation of AnaptysBio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AnaptysBio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AnaptysBio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AnaptysBio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.Note that the AnaptysBio information on this page should be used as a complementary analysis to other AnaptysBio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is AnaptysBio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.08) | Revenue Per Share 0.637 | Quarterly Revenue Growth 0.323 | Return On Assets (0.18) | Return On Equity (0.93) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.